| Project/Area Number |
25462274
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
Kuroda Junichiro 熊本大学, 大学院生命科学研究部(医), 助教 (90536731)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
倉津 純一 熊本大学, 大学院生命科学研究部(医), 教授 (20145296)
中村 英夫 熊本大学, 医学部附属病院, 講師 (30359963)
秀 拓一郎 熊本大学, 医学部附属病院, 診療講師 (40421820)
篠島 直樹 熊本大学, 医学部附属病院, 寄附講座教員 (50648269)
矢野 茂敏 熊本大学, 大学院生命科学研究部(医), 准教授 (60332871)
牧野 敬史 熊本大学, 医学部附属病院, 講師 (90381011)
|
|---|
| Research Collaborator |
MATSUMURA Yasuhiro
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | brain tumor / drug delivery system / tissue factor / antibody / ADC / drug delivery / DDS / 血管透過性 / 悪性グリオーマ / モノクローナル抗体 / ドラッグデリバリーシステム / がんと凝固 / fibrin / monoclonal antibody |
|---|
| Outline of Final Research Achievements |
We focused on brain tumor cell factor and tumor tissue environmental factor to develop DDS therapy for malignant brain tumor.Tissue factor is one of the trigger molecule for exogenous coagulation in malignant tumor. We examined drug delivery method using anti tissue factor factor monoclonal antibody. First of all, immunostaining of glioma was carried out, and it was confirmed that tissue factor was highly expressed as malignancy increased. Next, we conducted animal experiments in which the glioblastoma cell line was transplanted subcutaneously, and it was confirmed that the anti-tissue factor antibody highly accumulated in the tumor and did not accumulate in normal organs. It is expected to develop into an antibody drug complex using tissue factor antibody.
|
